Wooing Partners, Pharmacopeia Shifts DARA To Kidney Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
Cash-light firm’s move away from the crowded hypertension space could clinch a deal.
You may also be interested in...
Ligand Eyes Pharmacopeia Royalty Stream In Merger Deal
Stock-for-stock exchange is valued at $70 million, though DARA future still unclear.
Ligand Eyes Pharmacopeia Royalty Stream In Merger Deal
Stock-for-stock exchange is valued at $70 million, though DARA future still unclear.
FDA’s Cardio-Renal Division Kicks Off August With Three Approvals
The Medicines Co.’s IV therapy Cleviprex plus Novartis’ drug-drug combos, Exforge and Diovan HCT, are approved.